宫颈癌组织中miR-216b与FOXM1表达及与临床病理特征的关系

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (505 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究宫颈癌组织中微小RNA（miR）-216b与叉头框蛋白M1（FoxM1）表达及其与临床病理特征的关系。方法选取2016年3月~2019年3月华中科技大学同济医学院附属武汉市中心医院诊治的宫颈癌患者84例作为病例组，同期选择宫颈上皮内瘤变（CIN）患者40例作为CIN组，子宫良性病变患者40例作为对照组。采用实时荧光定量PCR检测各组miR-216b及FoxM1表达水平，比较其与临床病理特征的关系及相关性分析。结果病例组miR-126b表达水平显著低于CIN组及对照组，FOXM1表达水平显著高于CIN组及对照组，差异均有统计学意义（均P < 0.05）。miR-126b及FOXM1的表达与FIGO分期、肿瘤分化程度及浸润深度有关，而与年龄、病理类型、有无淋巴结转移及是否存在人乳头状瘤病毒（HPV）16/18感染无关。miR-126b水平与FOXM1水平呈负相关（r = -0.694，P = 0.001）。结论宫颈癌组织中miR-126b及FOXM1均异常表达，两者共同参与宫颈癌的发生发展过程，有可能成为宫颈癌诊断、治疗及预后评估的新肿瘤标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王梦漪卢宏达陈莉雷章

关键词 ：宫颈癌, 微小RNA-216b, 叉头框蛋白M1, 浸润

Abstract：Objective To study the expression of micro RNA (miR)-216b and forkhead box protein M1 (FOXM1) in cervical cancer and its relationship with clinicopathological features. Methods From March 2016 to March 2019, 84 cases with cervical cancer diagnosed and treated in the Central Hospital of Wuhan, Tongji Medical College of Huazhong University of Science and Technology were selected as case group. In the same period, 40 cases with cervical intraepithelial neoplasia (CIN) were selected as CIN group, and 40 cases with benign uterine lesions were used as control group. The expressions of miR-216b and FOXM1 in each group were detected by real-time fluorescent quantitative PCR. Its relationship with clinicopathological features were compared and the correlation was analyzed. Results The expression of miR-126b in case group was significantly lower than that in CIN group and control group, while the FOXM1 in case group was significantly higher than that in CIN group and control group, and the differences were statistically significant (all P < 0.05). The expression of miR-126b and FOXM1 were correlated with FIGO stage, degree of tumor differentiation and depth of infiltration, but not with age, pathological type, lymph node metastasis and human papillomavirus (HPV) 16/18 infection. The expression of miR-126b was negatively correlated with the expression of FOXM1 (r = -0.694, P = 0.001). Conclusion MiR-126b and FOXM1 are abnormally expressed in cervical cancer tissues. Both of them are involved in the occurrence and development of cervical cancer, and may become new tumor markers for cervical cancer diagnosis, treatment and prognosis evaluation.

Key words： Cervical cancer MiR-216b Forkhead box protein M1 Infiltration

基金资助:湖北省知识创新专项（自然科学基金）（2017CF B408）。

通讯作者: 雷章（1981.1-），男，博士，副主任医师；研究方向：妇科肿瘤、胃肠道肿瘤化放疗。

作者简介: 王梦漪（1985.7-），女，硕士；研究方向：妇科肿瘤、胃肠道肿瘤化放疗。

引用本文:

王梦漪卢宏达陈莉雷章. 宫颈癌组织中miR-216b与FOXM1表达及与临床病理特征的关系[J]. 中国医药导报, 2019, 16(35): 86-89.
WANG Mengyi LU Hongda CHEN Li LEI Zhang. Expression of miR-216b and FOXM1 in cervical cancer and its relationship with clinicopathological features. 中国医药导报, 2019, 16(35): 86-89.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I35/86

[1] 乔友林，赵宇倩.宫颈癌的流行病学现状和预防[J].中华妇幼临床医学杂志：电子版，2015，11（2）：1-6.
[2] 李侠，郝文胜，刘馨，等.贝伐单抗在中晚期宫颈癌中的应用[J].安徽医药，2018，22（12）：2283-2287.
[3] 王思念，吕进，张巧云，等.miRNA与肿瘤侵袭转移[J].现代肿瘤医学，2016，24（3）：485-487.
[4] Hua FF，Liu SS，Zhu LH，et al. MiRNA-338-3p regulatescervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway [J]. Eur Rev Med Pharmacol Sci，2017，21（23）：5342-5352.
[5] Zeng Y，Wang KX，Xu H，et al. Integrative miRNA analysis identifieshsa-miR-3154，hsa-miR-7-3，and hsa-miR-600 as potential prognostic biomarker for cervical cancer [J]. J Cell Biochem，2018，119（2）：1558-1566.
[6] 郑伟，郭晓华，董洁，等.miR-216b在体外培养细胞中加速长非编码RNA UCA1的降解[J].生物技术通讯，2017， 28（3）：227-232.
[7] 张艳，雷玉.FOXM1蛋白表达与人类宫颈癌的相关性[J].海南医学，2018，29（1）：7-10.
[8] FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of thevulva，cervix，and corpus uteri [J]. Int J Gynaecol Obstet，2014，125（2）：97-98.
[9] 张媛，贺桂芳，卞美璐.生物标记物对于宫颈癌的诊治和研究进展[J].中日友好医院学报，2017，31（5）：307-309.
[10] 张萍，刘玉武，哈提拉·吐尔逊，等.miRNA-101表达对子宫颈癌细胞丝状伪足形成的影响[J].中华妇产科杂志，2018，53（10）：715-717.
[11] 秦海霞，李少平，张全华，等.miRNA-375靶向磷脂酰肌醇激酶-3催化亚单位α对宫颈癌细胞增殖和迁移的影响[J].中国现代医学杂志，2018，28（33）：29-34.
[12] Wu X，Chen W，Cai H，et al. MiR-216 binhibits pancreatic cancer cell progression and promotes apoptosis bydown-regulating KRAS [J]. Arch Med Sci，2018，14（6）：1321-1332.
[13] Jana S，Sengupta S，Biswas S，et al. miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP [J]. Biochem Biophys Res Commun，2017，482（1）：126-133.
[14] He S，Liao B，Deng Y，et al. MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis [J]. BMC Cancer，2017，17（1）：673.
[15] Xie P，Cao H，Li Yi，et al. Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b [J]. Cancer Biomark，2017，21（1）：123-133.
[16] 程艳香，杨潇，陈干涛.miR-216b通过靶向调控Beclin-1的表达抑制宫颈癌细胞自噬[J].肿瘤防治研究，2016， 43（11）：954-958.
[17] Wang L，Lu J，Zhang H，et al. MicroRNA-876-5p inhibits the progression of glioblastoma multiforme by directly targeting Forkhead box M1 [J]. Oncol Rep，2019，41（1）：702-710.
[18] 马丽.miR-146a（rs2910164）基因多态性及miR-146a\ miR-133b的差异表达与宫颈癌发生发展的关系[D].新疆：新疆医科大学，2015.
[19] Wang W，Guo Z，Yu H，et al. MiR-216b inhibits osteosarcoma cell proliferation，migration，and invasion by targeting Forkhead Box M1 [J]. J Cell Biochem，2019， 120（4）：5435-5443.
[20] 程艳香，杨潇，陈干涛.miR-216b通过靶向调控Beclin-1的表达抑制宫颈癌细胞自噬[J].肿瘤防治研究，2016， 43（11）：954-958.